With improvements in diagnostic, therapeutic, and supportive therapies, the number of cancer survivors continues growing with over 20 million cancer survivors worldwide and an estimated 2/3 of adults with a cancer diagnosis who are anticipated to be alive in 5 years1. Due to this increase in survivors, major medical societies such as American Society of Clinical Oncology (ASCO), Institute of Medicine (IOM), and the Society for Immunotherapy of Cancer’s (SITC) have highlighted the need for strategies to improve the ongoing care of survivors and survivorship plans.2 The 4 basic tenets of a survivorship plan are surveillance, prevention, intervention and coordination. Surveillance is aimed at monitoring for recurrence, second cancers, and long term toxicities, prevention of these sequelae if possible, intervention if they are found, and lastly coordination between hospital and community-based doctors is essential for this plan to be effective.3 These needs are typically communicated to the patient’s general practitioner (GP)/primary care physician (PCP) by a “care plan” that outlines the patient’s oncology treatment course, potential long-term toxicity, the frequency of follow up visits, scans and links to community resources. New cancer therapies such as immunotherapy has resulted in significantly improved overall survivals in many advanced cancers, including those that had formerly been considered refractory.6,7,8 However, the short-, intermediate-, and long-term complications of these therapeutic agents are still being identified. Immune-mediated events, for example, can occur immediately after therapy initiation or even up to two years post treatment as a consequence of overstimulation of the immune system leading to autoimmunity with the potential for permanent or long-term sequelae.4,5